Summary statistics - qualitative results

EQA round: APLA2/26 - Antiphospholipid Antibodies

Deadline: 25.9.2026

Setup: Slovakia

AV = assigned value
CVP = consensus of all participants
CVPG = consensus of the participants' groups
>>> ... expected result
> ... acceptable result
± ... result not assessed

N_{tot} = total number of the results
N_{rel} = relative number of the results

N_{eva} = number of the results assessed
N_{suc} = number of successful results
S_{rel} = relative success

Test / Sample / Group	AV	N_{tot}	N_{rel} [%]	Result	Success N_{eva}	Success N_{suc}	Success S_{rel} [%]
(465) **anti-β2-glycoprotein 1 screening**		5			0		
Sample A		5			5	5	100
All results	CVP >>>	5	100	Negative			
Sample B		5			0		
All results	±	1	20	Inconclusive result (borderline)			
	±	4	80	Positive			
(467) **anti-β2-glycoprotein 1 IgG**		11			11	11	100
Sample A		11			11	11	100
All results	CVP >>>	11	100	Negative			
Sample B		11			11	11	100
All results	CVP >>>	11	100	Negative			
(468) **anti-β2-glycoprotein 1 IgM**		11			11	11	100
Sample A		11			11	11	100
All results	CVP >>>	11	100	Negative			
Sample B		11			11	11	100
All results	CVP >>>	11	100	Positive			
(461) **anti-cardiolipin screening**		6			6	6	100
Sample A		6			6	6	100
All results	CVP >>>	6	100	Negative			
Sample B		6			6	6	100
All results	CVP >>>	6	100	Positive			
(463) **anti-cardiolipin IgG**		11			11	11	100
Sample A		11			11	11	100
All results	CVP >>>	11	100	Negative			
Sample B		11			11	11	100
All results	CVP >>>	11	100	Negative			
(464) **anti-cardiolipin IgM**		11			9	9	100
Sample A		11			11	11	100
All results	CVP >>>	11	100	Negative			
Sample B		11			9	9	100
All results (without individual groups)	CVP >>>	9	82	Positive			
(166) Thermo Fisher	±	2	18	Inconclusive result (borderline)			